Patients with active rheumatoid arthritis but only few tender and swollen joints: a subgroup with impaired short term outcome

被引:1
作者
Fiehn, C. [1 ]
Kessler, S. [1 ]
Drexler, W. [1 ]
Lorenz, H. M. [1 ,2 ]
机构
[1] Ctr Rheumat Dis Baden Baden, D-76530 Baden Baden, Germany
[2] Univ Heidelberg, Dept Internal Med 5, Rheumatol Sect, D-6800 Mannheim, Germany
关键词
Rheumatoid arthritis; Disease activity; Pain; Function; RANDOMIZED CONTROLLED-TRIAL; METHOTREXATE; VALIDITY; CRITERIA; VALUES; DAS28;
D O I
10.1007/s00296-008-0753-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The disease activity score of 28 joints (DAS28) is now commonly used for the guidance of treatment decisions in rheumatoid arthritis (RA). The goal of this work was to determine whether patients with DAS28 > 3.2 but less than 2 swollen and 2 tender joints respond differently to treatment than patients with a higher number of active joints. One hundred and ninety two patients with active RA treated in a rheumatology hospital as in-patients were studied prospectively. At admission (T1), release (T2) and 3 months after release (T3) disease activity (DAS28-CRP at T1 + 2, RADAI at T1 + 3), pain (numeric scale at T1 - 3) and function (FFbH at T1 + 3) were measured. A total of 148 patients had two or more (group 1) and 44 less than 2 swollen and tender joints at admission (group 2) but both groups had similar over all DAS28-scores. The groups significantly differed in their outcome after 3 months: group 1 had a significant better reduction of disease activity, pain and functional deficit (p < 0.001 for the fulfilment of defined response criteria and p < 0.05 for comparison of the mean values for pain and function) in comparison to group 2. Although the numbers were small sub-analysis suggested that the differences might be due to a better response to newly administered DMARD and TNF-alpha-inhibitor therapy in group 1. Active RA patients with less than 2 swollen and 2 tender joints represent a subgroup with lower response to treatment with DMARD or TNF-alpha-inhibitors. This has to be taken into account in the management of these patients.
引用
收藏
页码:655 / 661
页数:7
相关论文
共 18 条
  • [11] Leeb BF, 2007, J RHEUMATOL, V34, P2382
  • [12] Infliximab and methotrexate in the treatment of rheumatoid arthritis
    Lipsky, PE
    van der Heijde, DMFM
    St Clair, EW
    Furst, DE
    Breedveld, FC
    Kalden, JR
    Smolen, JS
    Weisman, M
    Emery, P
    Feldmann, M
    Harriman, GR
    Maini, RN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1594 - 1602
  • [13] Raspe HH, 1999, WOHNORTNAHE BETREUUN, P164
  • [14] VALIDITY AND RELIABILITY OF THE 28-JOINT COUNT FOR THE ASSESSMENT OF RHEUMATOID-ARTHRITIS ACTIVITY
    SMOLEN, JS
    BREEDVELD, FC
    EBERL, G
    JONES, I
    LEEMING, M
    WYLIE, GL
    KIRKPATRICK, J
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (01): : 38 - 43
  • [15] Soubrier M, 2006, J RHEUMATOL, V33, P1243
  • [16] Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis - Comparison with the preliminary American College of Rheumatology and the World Health Organization International League Against Rheumatism criteria
    vanGestel, AM
    Prevoo, MLL
    vantHof, MA
    vanRijswijk, MH
    vandePutte, LBA
    vanRiel, PLCM
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (01): : 34 - 40
  • [17] *VRA, 2007, OUTC BENCHM RHEUM AK
  • [18] Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study - Comparison of patients according to their eligibility for major randomized clinical trials
    Zink, Angela
    Strangfeld, Anja
    Schneider, Matthias
    Herzer, Peter
    Hierse, Franka
    Stoyanova-Scholz, Maria
    Wassenberg, Siegfried
    Kapelle, Andreas
    Listing, Joachim
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (11): : 3399 - 3407